Part 11 Redux? Comment Period Extension, Meeting Rescheduling Mulled
This article was originally published in The Gray Sheet
Executive Summary
FDA is considering reopening the comment period on the electronic records and signatures rule and may reschedule a public meeting to discuss changes, according to agency staff